Validation of 4β-hydroxycholesterol and evaluation of other endogenous biomarkers for the assessment of CYP3A activity in healthy subjects

Validation of 4β-hydroxycholesterol and evaluation of other endogenous biomarkers for the assessment of CYP3A activity in healthy subjects

Item
http://www.wikidata.org/entity/Q34570949
Ritonavir is the best alternative to ketoconazole as an index inhibitor of cytochrome P450-3A in drug-drug interaction studies.miRNA-27b levels are associated with CYP3A activity in vitro and in vivo.Validation of a microdose probe drug cocktail for clinical drug interaction assessments for drug transporters and CYP3A.Endogenous Probes for Drug Transporters: Balancing Vision With Reality.CYP3A activity: towards dose adaptation to the individual.UHPLC-MS/MS bioanalysis of urinary DHEA, cortisone and their hydroxylated metabolites as potential biomarkers for CYP3A-mediated drug-drug interactions.Perspective: 4β-hydroxycholesterol as an emerging endogenous biomarker of hepatic CYP3A.An Exposure-Response Modeling Approach to Examine the Relationship Between Potency of CYP3A Inducer and Plasma 4β-Hydroxycholesterol in Healthy Subjects.Relationships between Endogenous Plasma Biomarkers of Constitutive Cytochrome P450 3A Activity and Single-Time-Point Oral Midazolam Microdose Phenotype in Healthy Subjects.Coproporphyrins I and III as Functional Markers of OATP1B Activity: In Vitro and In Vivo Evaluation in Preclinical Species.Comparative performance of oral midazolam clearance and plasma 4β-hydroxycholesterol to explain interindividual variability in tacrolimus clearance.Identification of ω- or (ω-1)-Hydroxylated Medium-Chain Acylcarnitines as Novel Urinary Biomarkers for CYP3A Activity.Impact of genetic and nongenetic factors on interindividual variability in 4β-hydroxycholesterol concentration.Sterol 27-hydroxylase gene dosage and the antiatherosclerotic effect of Rifampicin in mice.Differences in the Serum 4β-hydroxycholesterol Levels of Patients with Chronic HCV Infection: A Possible Impact on the Efficacy and Safety of IFN-free Treatment.CYP3A Specifically Catalyzes 1β-Hydroxylation of Deoxycholic Acid: Characterization and Enzymatic Synthesis of a Potential Novel Urinary Biomarker for CYP3A Activity.The cytochrome P450 isoenzyme and some new opportunities for the prediction of negative drug interaction in vivo.
P2860

Validation of 4β-hydroxycholesterol and evaluation of other endogenous biomarkers for the assessment of CYP3A activity in healthy subjects

Item
http://www.wikidata.org/entity/Q34570949
description
2014 nî lūn-bûn
@nan
2014 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Validation of 4β-hydroxycholes ...... A activity in healthy subjects
@ast
Validation of 4β-hydroxycholes ...... A activity in healthy subjects
@en
Validation of 4β-hydroxycholes ...... A activity in healthy subjects
@nl
type
label
Validation of 4β-hydroxycholes ...... A activity in healthy subjects
@ast
Validation of 4β-hydroxycholes ...... A activity in healthy subjects
@en
Validation of 4β-hydroxycholes ...... A activity in healthy subjects
@nl
prefLabel
Validation of 4β-hydroxycholes ...... A activity in healthy subjects
@ast
Validation of 4β-hydroxycholes ...... A activity in healthy subjects
@en
Validation of 4β-hydroxycholes ...... A activity in healthy subjects
@nl
P1433
P1476
P2093
P2860
P304
P31
P356
P407
P433
P478
P577
P5875
P698
P921
P932
P356
P1433
P1476
Validation of 4β-hydroxycholes ...... A activity in healthy subjects
@en
P2093
P2860
P304
P31
P356
P407
P433
P478
P577
P5875
P698
P921
P932